We recently proposed miR-142-3p as a molecular player in inflammatory synaptopathy, a new pathogenic hallmark of multiple sclerosis (MS) and of its mouse model experimental autoimmune encephalomyelitis (EAE), that leads to neuronal loss independently of demyelination. MiR-142-3p seems to be unique among potential biomarker candidates in MS, since it is an inflammatory miRNA playing a dual role in the immune and central nervous systems. Here, we aimed to verify the impact of miR-142-3p circulating in the cerebrospinal fluid (CSF) of MS patients on clinical parameters, neuronal excitability and its potential interaction with disease modifying therapies (DMTs).
MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis / De Vito, Francesca; Musella, Alessandra; Fresegna, Diego; Rizzo, Francesca Romana; Gentile, Antonietta; Bassi, Mario Stampanoni; Gilio, Luana; Buttari, Fabio; Procaccini, Claudio; Colamatteo, Alessandra; Bullitta, Silvia; Guadalupi, Livia; Caioli, Silvia; Vanni, Valentina; Balletta, Sara; Sanna, Krizia; Bruno, Antonio; Dolcetti, Ettore; Furlan, Roberto; Finardi, Annamaria; Licursi, Valerio; Drulovic, Jelena; Pekmezovic, Tatjana; Fusco, Clorinda; Bruzzaniti, Sara; Hornstein, Eran; Uccelli, Antonio; Salvetti, Marco; Matarese, Giuseppe; Centonze, Diego; Mandolesi, Georgia. - In: NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. - ISSN 0305-1846. - (2021). [10.1111/nan.12765]
MiR-142-3p regulates synaptopathy-driven disease progression in multiple sclerosis
Licursi, Valerio;Salvetti, Marco;
2021
Abstract
We recently proposed miR-142-3p as a molecular player in inflammatory synaptopathy, a new pathogenic hallmark of multiple sclerosis (MS) and of its mouse model experimental autoimmune encephalomyelitis (EAE), that leads to neuronal loss independently of demyelination. MiR-142-3p seems to be unique among potential biomarker candidates in MS, since it is an inflammatory miRNA playing a dual role in the immune and central nervous systems. Here, we aimed to verify the impact of miR-142-3p circulating in the cerebrospinal fluid (CSF) of MS patients on clinical parameters, neuronal excitability and its potential interaction with disease modifying therapies (DMTs).| File | Dimensione | Formato | |
|---|---|---|---|
|
De Vito et al. - MiR-142-3p_2021.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
2.41 MB
Formato
Adobe PDF
|
2.41 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
